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Abstract
Background It is not known how smoking affects the initial presentation of a wide range
of chronic and acute cardiovascular diseases (CVDs), nor the extent to which associ-
ations are heterogeneous. We estimated the lifetime cumulative incidence of 12 CVD
presentations, and examined associations with smoking and smoking cessation.
Methods Cohort study of 1.93 million people aged 30years, with no history of CVD, in
1997–2010. Individuals were drawn from linked electronic health records in England,
covering primary care, hospitalizations, myocardial infarction (MI) registry and cause-
specific mortality (the CALIBER programme).
Results During 11.6 million person-years of follow-up, 114 859 people had an initial non-
fatal or fatal CVD presentation. By age 90 years, current vs never smokers’ lifetime risks
varied from 0.4% vs 0.2% for subarachnoid haemorrhage (SAH), to 8.9% vs 2.6% for per-
ipheral arterial disease (PAD). Current smoking showed no association with cardiac
arrest or sudden cardiac death [hazard ratio (HR)¼1.04, 95% confidence interval (CI)
0.91–1.19).The strength of association differed markedly according to disease type: sta-
ble angina (HR¼1.08, 95% CI 1.01–1.15),transient ischaemic attack (HR¼ 1.41, 95% CI
1.28-1.55), unstable angina (HR¼ 1.54, 95% CI 1.38–1.72), intracerebral haemorrhage
(HR¼1.61, 95% CI 1.37–1.89), heart failure (HR¼ 1.62, 95% CI 1.47–1.79), ischaemic stroke
(HR¼1.90, 95% CI 1.72–2.10), MI (HR¼ 2.32, 95% CI 2.20–2.45), SAH (HR¼ 2.70, 95% CI
2.27–3.21), PAD (HR¼5.16, 95% CI 4.80–5.54) and abdominal aortic aneurysm (AAA)
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(HR¼5.18, 95% CI 4.61–5.82). Population-attributable fractions were lower for women
than men for unheralded coronary death, ischaemic stroke, PAD and AAA. Ten years
after quitting smoking, the risks of PAD, AAA (in men) and unheralded coronary death
remained increased (HR¼ 1.36, 1.47 and 2.74, respectively).
Conclusions The heterogeneous associations of smoking with different CVD presenta-
tions suggests different underlying mechanisms and have important implications for
research, clinical screening and risk prediction.
Key words: Association study, cardiovascular outcomes, epidemiology, initial presentation, lifetime risks, primary
prevention, smoking, risk prediction, risk stratification
Introduction
Cigarette smoking is known to be a major modifiable risk
factor for cardiovascular diseases (CVDs). Its relationship
with cardiovascular diseases and the reduction in risk fol-
lowing smoking cessation1 and implementation of compre-
hensive smoke-free legislations is well documented.2–4 The
focus of previous smoking research has generally been on
final manifestations (CVD mortality)5 or on one or two
non-fatal diseases, usually acute myocardial infarction
(MI) and stroke.4,6 Other CVDs, for example heart fail-
ure7,8 or peripheral arterial disease (PAD),9 have been less
commonly studied and the initial lifetime presentation of a
wide range of acute and chronic, non-fatal and fatal CVDs
has not been investigated in the same study population. In
the 21st century, with rapid declines in the incidence of MI
and stroke,10,11 chronic conditions such as PAD, heart fail-
ure and stable angina are becoming common initial presen-
tations of CVD. Studying and comparing the initial
presentation of a wide range of CVDs in the same popula-
tion has been difficult because of the need for large cohorts
with detailed clinical follow-up, covering hospital and am-
bulatory care. Recently, it has been suggested that linked
electronic health record (EHR) data might provide the stat-
istical scale and clinical resolution necessary for this
research.12
Fundamental, inter-related questions concerning disease
mechanism, public health and risk prediction remain un-
answered and are addressed as the aims of the present
study. First, what is the lifetime risk of current and ex-
smoking for each disease? Lifetime risk estimates have
been recently reported for aggregates of risk factors (not
specific to smoking status) and aggregates of coronary
heart disease (CHD) and CVD,13 but not for a wide range
of specific cardiovascular phenotypes. Second, to what ex-
tent do smoking associations differ according to each spe-
cific CVD? Some variation in associations between
smoking and different cardiovascular phenotypes is ex-
pected, given that smoking induces acute responses, includ-
ing increases in blood pressure, heart rate or pro-
thrombotic state; and chronic adaptation through increases
in levels of low-density lipoprotein cholesterol, fibrinogen
and platelet aggregation.14–16 For cancers, aetiological in-
sights have come from the observation that smoking has
no association with some (e.g. glioma), modest with others
(e.g. stomach or kidney cancer relative risks for current vs
non-smokers are 1.5–2.0) and very strong for lung cancer
(relative risks of 15–30).17 As in cancer research, the study
of heterogeneity in associations across CVD phenotypes
could provide important aetiological insights and guide the
design and interpretation of other studies. Third, how does
Key Messages
• This paper presents a population-based cohort analysis of contemporary electronic health records from more than
1.9 million adults with more than 100 000 initial presentations of 12 different non-fatal and fatal, acute and chronic
cardiovascular diseases.
• We demonstrate that current smoking has highly heterogeneous associations with different types of cardiovascular disease.
• In particular we report: associations with chronic conditions which have seldom been studied in large-scale cohorts,
such as heart failure (moderate association), peripheral arterial disease (very strong association) and chronic stable
angina (weak association); and lack of association with sudden cardiac death and ventricular arrhythmia.
• Our findings suggest differences in underlying disease mechanisms, and have important implications for risk predic-
tion, clinical practice and aetiological research.
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the smoking effect for each CVD differ among men and
women,6 at older ages, or among people with hypertension
or diabetes? Fourth, what is the population-attributable
fraction (PAF) for each disease and what is the contempor-
ary relevance of clinically recorded smoking data in the light
of recent policy such as financial rewards in primary care
for smoking assessment and public smoking bans? Fifth, if
smoking does have disease-specific associations, what are
the implications for risk prediction for primary prevention?
Currently used tools are based on a common estimate of
smoking association with aggregates of CVD or CHD.
However, because initial occurrence of one CVD strongly
influences the development of another [e.g. transient ischae-
mic attack (TIA) predisposes to MI and stroke), the ability
to predict different forms of CVD more precisely might offer
the potential for earlier initiation of preventive therapies.
We addressed these questions using a contemporary co-
hort18–20 based on linked EHRs across primary care, sec-
ondary care, disease registry and death records of patients
in England, with 6 years of median follow-up.
Methods
Study population
A cohort of 1 937 360 patients drawn from individuals
registered in the general practices in England contributing
with data to the CALIBER programme, between January
1997 and March 2010, was analysed. Patient data were
linked across four data sources (Appendix 1.1, see
Supplementary data available at IJE online); the Clinical
Practice Research Datalink (CPRD); the Myocardial
Ischaemia National Audit Project registry (MINAP);
Hospital Episodes Statistics (HES); and the Office of
National Statistics (ONS).18 Patients were eligible for inclu-
sion when they were aged 30 years and had been regis-
tered in a practice meeting research data recording
standards for at least 1 year. Patients with missing record of
sex, those with history of CVD and those pregnant within
6 months of the eligibility date were excluded (Appendix
1.2, see Supplementary data available at IJE online).
Smoking status
Patient self-reported smoking status was prospectively col-
lected and coded by general practitioners or practice nurses
on the date of consultation in CPRD. The most recent
smoking record before study entry was used to classify in-
dividuals as never, ex- or current smokers, and those iden-
tified as current smokers with no smoking record within
the 3 years before study entry were reclassified as having
missing smoking data. Never smokers who had a record of
smoking at any time before baseline were reclassified as
ex-smokers. Ex-smokers were grouped into categories of
time since quitting (<2, 2–5, 5–10, >10 years and missing)
using the date of smoking interruption recorded in CPRD
on or before study entry, which was available for 33.7% of
ex-smokers. The median time between recorded baseline
status and study entry was 1.0 year.
Covariates
Covariates considered in the analysis were: sex, age, index
of multiple deprivation, diabetes mellitus, body mass index
(BMI), systolic blood pressure (SBP), total and high-density
lipoprotein (HDL) cholesterol and medication use (blood
pressure-lowering drugs, statins, oestrogen oral contracep-
tives and hormone replacement therapy). Baseline covari-
ates were defined as the most recent measurement (or
prescription) recorded in CPRD up to 1 year before study
entry. Patients were defined as diabetic if they had a diag-
nosis or prescription for diabetes prior to the index date.
Covariate definitions can be found at [http://www.caliber
research.org/portal/].
Endpoints
The primary endpoints were the initial presentation of
non-fatal or fatal CVD across data sources. Diseases
studied were: stable angina, unstable angina, MI, unher-
alded coronary death, heart failure; a composite of ven-
tricular arrhythmia, cardioversion, cardiac arrest or
sudden cardiac death (CA-SCD); TIA, ischaemic stroke,
subarachnoid haemorrhage (SAH), intracerebral haemor-
rhage, PAD and abdominal aortic aneurysm (AAA).
Secondary endpoints were: composite CVD (all cardiovas-
cular endpoints except stable angina); ST-elevation MI
(STEMI); and non-ST-elevation MI (NSTEMI). Diagnosis
codes for each endpoint can be found at [http://www.cali
berresearch.org/portal/] (Appendix 1.3, see Supplementary
data available at IJE online).
Statistical analysis
Patient follow-up was started on the date on which all eli-
gibility criteria were met after 1 January 1997 and was
censored on the date of first CVD presentation, death from
other causes, last data collection from CPRD (25 March
2010) or deregistration from the practice, whichever
occurred first. For each CVD, the lifetime cumulative inci-
dence was estimated with Cox proportional hazard models
adjusted for the competing risk of initial presentation with
another CVD or death from other causes, using age as the
time scale. In primary analyses, the relationship between
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current vs never smokers for each endpoint was assessed
using age-adjusted, multiply imputed Cox proportional
hazard models. The baseline hazard function of each
model was stratified by sex and practice. Never smokers
were the reference category. Multiple imputation was used
to replace missing values in exposure and in risk factors. It
was implemented using the mice21 algorithm in the statis-
tical package R. Imputation models were estimated separ-
ately for men and women and included: (i) all the baseline
covariates used in the main analysis (age, quadratic age,
diabetes, smoking, systolic blood pressure, total choles-
terol, HDL cholesterol, index of multiple deprivation); (ii)
prior (between 1 and 4 years before study entry) and post
(between 0 and 1 year after study entry) averages of con-
tinuous covariates in the main analysis; (iii) baseline meas-
urements of covariates not considered in the main analysis
(diastolic blood pressure, alcohol intake, white cell count,
haemoglobin, creatinine, alanine transferase); (iv) baseline
medications (statins, blood pressure-lowering medication,
low-dose aspirin, loop diuretics, oestrogen oral contracep-
tives and hormone replacement therapy); (v) coexisting
medical conditions (history of depression, cancer, renal
disease, liver disease and chronic obstructive pulmonary
disease); and (vi) the Nelson-Aalen hazard and the event
status for each of the 12 endpoints analysed.22 Non-
normally distributed variables were log-transformed for
imputation and exponentiated back to their original scale
for analysis. Five multiply imputed datasets were gener-
ated, and Cox models were fitted to each dataset.
Coefficients were combined using Rubin’s rules. The
Kolmogorov–Smirnov test was used to compare the distri-
bution of observed vs imputed log-transformed covariates.
Assuming independence between initial presentations,
heterogeneity in associations across CVD endpoints was
assessed using the s2 statistic.23 PAFs associated with cur-
rent and former smoking were calculated using the Stata
command punafcc. The clinical utility of smoking to
predict the risk of CVD was assessed by estimating the im-
provement in risk discrimination (difference in the
C-index) resulting from including smoking status into a
Cox proportional hazard model with only age and sex,
among patients aged 40–74 years (Vascular Health
Screening target group in England).
In secondary analyses, we evaluated effect modification
by sex and baseline age, diabetes, hypertension, implementa-
tion of the English smoke-free legislation period (before/after
1 July 2007 periods) and introduction of financial reward for
recording of smoking information (before/after 1 April 2004)
by including an interaction term between smoking status and
the appropriate variable. Associations between the outcomes
and time since smoking cessation were assessed using current
and never smokers as reference groups. In sensitivity analyses:
we compared imputed (including individuals with observed
and imputed smoking status data, as in the primary analysis)
and complete case [including only patients with recorded
smoking status data (n¼ 1 413 749)] results, and examined
associations separately by ignoring primary care recorded
endpoints, restricting the analyses to fatal events and includ-
ing first occurrence of each CVD endpoint irrespective of
other earlier CVD presentation. Analyses were performed
with R 3.0 and Stata 12.
Ethical considerations
Approval was granted by the Independent Scientific
Advisory Committee of the Medicines and Healthcare
Products Regulatory Agency and the MINAP Academic
Group. We registered the protocol at: [http://clinicaltrials.
gov] (NCT01164371).
Results
Patient characteristics
A total of 1 937 360 subjects experienced 114 859 fatal or
non-fatal CVD endpoints over 11.6 million person-years of
follow-up (median 5.5 years per person). Of the total num-
ber of initial presentations of CVD events recorded, 14.1%
were MI, 12.5% heart failure, 11.5% stable angina,
10.2% TIA, PAD 10.0%, ischaemic stroke 5.3%, unstable
angina 4.9%, CA-SCD 2.9%, AAA 2.7%, intracerebral
haemorrhage 2.1% and SAH 1.1%.
Of patients with recorded smoking status (1.4 million/
1.9 million), 20.3% were active smokers (23.6% of men
and 17.5% of women) and 16.2% ex-smokers (18.0% and
14.7%, respectively); 47% of current smokers and 49.1%
of ex-smokers were women (Table 1). A description of
smoking patterns of individuals included in the study by
sex, age and birth cohort is shown in Appendix 1.4 (see
Supplementary data available at IJE online). The propor-
tion of ex-smokers and the sex differences in proportions
of never smokers increased with higher baseline age from
13.9% in the 30–39 year group to 21.6% in those aged 80
years or more, and from 5.0% to 21.7%, respectively.
Compared with former or never smokers, current smokers
were younger, of white ethnicity and more socially
deprived. Ex-smokers received statin and antihypertensive
medication more frequently and diabetes was also more
common among men.
Lifetime incidence of CVDs
The lifetime incidence of CVD amongst current, ex- and
never smokers differed markedly across endpoints (Figure 1).
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The highest estimates were observed for PAD, occurring
by age 90 years in 8.9% of current smokers and in
2.6% of never smokers, see Appendix 2.1 (available as
Supplementary data at IJE online). Current smokers had
an approximately 10-year earlier onset and higher and per-
sisting incidence of MI, PAD and AAA through to older
age. Smaller differences in age of onset and incidence were
observed for other types of cerebrovascular phenotypes,
unstable angina or heart failure. No differences according
to smoking status were seen in lifetime risks for stable an-
gina or CA-SCD.
Current smoking and CVD
Current smokers had increased hazard of most, but not all
types of CVD (Figure 2). CA-SCD was not associated with
smoking (adjusted HR¼1.04, 95% CI 0.91–1.19).
Marked differences in the strength of associations were
observed across endpoints (I2¼ 99.2%, s2¼ 0.27), ranging
from: weak with stable angina (adjusted HR¼ 1.08, 95%
CI 1.01–1.15); moderate with TIA, unstable angina, intra-
cerebral haemorrhage and heart failure (range 1.41 to
1.62); strong with ischaemic stroke and MI (adjusted HRs
1.90 and 2.32, respectively); and very strong with AAA,
PAD, unheralded coronary death and SAH (range 2.70 to
5.18). Adjustment for other risk factors (see Appendix
2.2.1, available as Supplementary data at IJE online),
comparison between complete case vs imputed data
(see Appendix 2.2.2, available as Supplementary data at
IJE online), restricting data sources (see Appendix 2.2.3,
available as Supplementary data at IJE online) and analy-
sing endpoints defined as first events (irrespective of other
earlier CVD presentation; see Appendix 2.2.4, available as
Supplementary data at IJE online) made little if any differ-
ence to our finding of highly heterogeneous associations.
Adjusted HRs for STEMI and NSTEMI were 2.60 (95%
CI 2.35–2.88) and 2.30 (95% CI 2.07–2.56), respectively.
Interactions with sex
The relationship between current smoking and PAD was
stronger in men than in women (adjusted HR¼ 5.72, 95%
CI 5.24–6.24; compared with 4.17, 95% CI 3.68–4.73;
interaction P-value 0.0005; see Figure 3). In contrast, current
smoking showed stronger associations among women than
in men for MI (adjusted HR¼ 2.51, 95% CI 2.35–2.73 vs
2.18, 95% CI 2.03–2.32; interaction P-value 0.05).
Population-attributable fractions
Overall PAF for combined CVDs for current smoking was
10.6% (95% CI 10.5%-10.8%). This summary estimate
masked a wide range, from 2.2% for stable angina to
16.3% for AAA and PAD (see Appendix 2.3, available as
Supplementary data at IJE online). PAF estimates were
markedly lower for women than men for unheralded
Figure 1. Lifetime cumulative incidence of 12 CVD phenotypes stratified by baseline smoking status. Shaded areas indicate confidence intervals.
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coronary death (8.7% vs 14.3%), ischaemic stroke (8.1%
vs 12.0%), PAD (13.7% vs 18.9%) and AAA (13.9% vs
18.5%; see Figure 4).
Associations among high-risk groups
Age modified the smoking associations in disease-specific
patterns. For angina and CA-SCD, higher HRs among
current smokers were confined to the younger age groups
(adjusted HR¼ 1.48, 95% CI 1.15–1.90, interaction
P-value <0.0001; and 1.40, 95% CI 1.03–1.90, interaction
P-value 0.05, respectively, among 30–39-year-olds). For
other diseases, although the HR tended to decline with
age, estimates remained elevated into the 8th and 9th dec-
ades of life (Appendices 2.4.1, 2.4.2 and 2.4.3, available as
Supplementary data at IJE online).
Figure 3. Age-adjusted hazard ratios of 12 CVDs comparing current vs never smokers in men and women. Cardiac arrest/SCD, cardiac arrest,
ventricular fibrillation and sudden cardiac death; CI, confidence interval; HR, age-adjusted hazard ratio from Cox proportional hazard models with
baseline hazard function stratified by general practice and adjusted for baseline age (linear and quadratic terms). *P-value for interaction 0.05
(P¼ 0.05 for myocardial infarction and P¼ 0.0005 for peripheral arterial disease).
Figure 2. Age-adjusted hazard ratios of 12 CVDs comparing current vs never smokers. Cardiac arrest/SCD, cardiac arrest, ventricular fibrillation and
sudden cardiac death; CI, confidence interval; HR, hazard ratio derived from Cox proportional hazard models with baseline hazard function stratified
by sex and general practice and adjusted for baseline age (linear and quadratic terms); MI, myocardial infarction. The vertical dotted line indicates the
HR of the composite cardiovascular disease endpoint.
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Relationships between current smoking and CVD pheno-
types were weaker in individuals with diabetes or hyperten-
sion. Weaker associations in smoking among people with
diabetes compared with those without diabetes were found
for unstable angina, PAD and MI (percentage decreases
were 43.4%, 42.4% and 28.0%, respectively; interaction
P-values 0.04, <0.0001 and 0.001, respectively; see
Appendix 2.4.4, available as Supplementary data at IJE
online). Greater differences between patients with and with-
out hypertension were found for PAD (23.3% percentage
decrease, interaction P-value 0.004; see Appendix 2.4.5,
available as Supplementary data at IJE online).
Smoking cessation
The hazard of all CVDs (except CA-SCD) gradually
decreased with time after smoking cessation, with hazard
ratios ranging between 0.43 and 1.03 for the first 2 years
after quitting, and between 0.25 and 1.09 for the period
after 10 years of quitting, compared with current smokers
(Figure 5). Although individuals generally achieved the risk
level of never smokers after 10 years of quitting (see
Appendix 2.5, available as Supplementary data at IJE on-
line), estimates for PAD (HR¼ 1.36, 95% CI 1.11–1.67)
and AAA (HR¼ 1.47, 95% CI 1.10–1.95) in men, and un-
heralded coronary death (HR¼ 2.74, 95% CI 1.36–5.51)
in women remained increased.
Public health interventions
Associations with smoking status were similar in the peri-
ods before and after the introduction of two public health
interventions on smoking, the financial reward for collec-
tion of smoking data (see Appendix 2.6.1, available as
Supplementary data at IJE online) and the smoking ban in
England (Appendix 2.6.2, available as Supplementary data
at IJE online).
Discriminative ability of smoking status
The c-index increment when smoking coefficients were
included in risk prediction models adjusted for age and sex
varied from 0.2% for stable angina and CA-SCD to 7.1%
for SAH, compared with an increment of 1.6% for the
CVD composite (see Figure 6).
Discussion
This population-based cohort analysis of contemporary
electronic health records (1997–2010) from more than 1.9
million adults with more than 100 000 initial presentations
of non-fatal and fatal CVDs showed that current smoking
has highly heterogeneous associations with different types
of disease. Estimates ranged from none for CA-SCD,
through weak for stable angina, to very strong for AAA
and PAD. Our findings point to underlying differences in
disease aetiology, and have implications for risk prediction
in clinical practice.
To our knowledge, we are the first to report the lifetime
risks of different CVDs according to smoking status.
Previous reported estimates of lifetime risks were calculated
for aggregated risk factors and aggregated endpoints.13
Current guidelines recommend managing CVDs as a single
family of related diseases,24 but our findings suggest
Figure 4. Population-attributable fractions (%) for 12 CVDs associated with current smoking in men and women. Cardiac arrest/SCD, cardiac arrest,
ventricular fibrillation and sudden cardiac death; CI, confidence interval; CVD, cardiovascular diseases; PAF, population-attributable fraction derived
from Cox proportional hazard models with baseline hazard function stratified by sex and general practice and adjusted for baseline age (linear and
quadratic terms).
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important differences. The disease with the highest absolute
lifetime risk among current smokers is PAD (9% risk by age
90 years, compared with 3% risk among never smokers), a
disease that is considerably less studied than MI. Evaluating
lifetime risks may help in counselling patients and in starting
preventive measures at an appropriately early age.
The heterogeneous association we observed between
current smoking and 12 different acute and chronic CVDs
has not previously been reported. This is because previous
studies have not collected data on this range of clinical
phenotypes, or have lacked statistical power. Nonetheless,
our findings are consistent with previously reported associ-
ations with a limited number of diseases,25–28 with stron-
ger associations found for MI than for stable or unstable
angina,29,30 for unstable than for stable angina31 and
for SAH than for other types of stroke.32,33 Stronger
associations were also seen in younger than in older
individuals.27,33
Figure 6. Increment in c-index associated with inclusion of smoking status in CVD phenotype-specific models containing sex and age. The vertical
bold line indicates the increment in the c-index estimate for the CVD composite (increment index¼ 0.016, 95% CI 0.015-0.017), compared with a sex-
and age-adjusted model with c-index¼ 0.73 (95% CI 0.72-0.73). Cardiac arrest/SCD, cardiac arrest, ventricular fibrillation and sudden cardiac death;
CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular diseases.
Figure 5. Age-adjusted hazard ratios of 12 CVDs for duration of smoking cessation vs current smokers. Cardiac arrest/SCD, cardiac arrest, ventricular
fibrillation and sudden cardiac death; CI, confidence interval; HR, hazard ratio derived from Cox proportional hazard models with baseline hazard
function stratified by sex and general practice and adjusted for baseline age (linear and quadratic terms).
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The heterogeneity in estimates we observed between
smoking and different manifestations of CVD likely re-
flects differences in pathophysiological mechanisms. The
absence of association with CA-SCD, for instance, con-
trasts with the strong association with acute MI and is con-
sistent with mechanistic differences in the risk of these
disorders reflected in the observation that the heart rate
profile during exercise associates with CA-SCD but not
with MI.34 Other investigators have reported an increased
risk of SCD among current smokers,35,36 although this ap-
parent contradiction may be because they did not focus on
SCD as an initial presentation of CVD. The hazard of all
CVDs decreased after smoking cessation, with faster de-
creases observed for MI and PAD (by 50–57% within 2
years of quitting), and individuals generally achieving the
level of never smokers 10 years after quitting. Our findings
are consistent with reports from previous studies of MI27
and stroke37,38 among ex-smokers. The rapid decreases in
risk of MI and PAD after smoking cessation suggest that
the initial presentation of these two CVDs is likely to be
triggered by acute effects of smoke exposure acting on the
vascular system. This finding is consistent with the obser-
vation of sharp declines in rates of acute MI early after the
introduction of smoke-free legislation, and effects increas-
ing over time since implementation.3
We report sex differences in public health impact which
might arise if no one smoked. In a meta-analysis of 75 co-
horts and 2.4 million people recruited in 1956–2000,
women smokers had a 25% higher risk of aggregates of
CHD than men smokers, with differences found only in
the 60–69-year-old group.6 These results are consistent
with our estimates for MI but contradict those for PAD, an
endpoint not reported in many studies.
PAFs have not previously been compared across the ini-
tial presentation of these 12 CVDs. Assuming a causal rela-
tionship, abolishing smoking would prevent a higher
proportion of some diseases (e.g. AAA, PAD) than others
(e.g. CA-SCD, angina). Moreover, for four of the diseases
studied (unheralded coronary death, ischaemic stroke,
SAH and intracerebral haemorrhage), this proportion
would be substantially higher among men.
We found strong evidence that incorporating a single
generic effect of smoking in widely used risk prediction
models for CVD aggregates will overestimate the risk of
some diseases (e.g. heart failure or CA-SCD) and underesti-
mate the risk of others (e.g. PAD). Differences in the dis-
criminative capacity of smoking across types of CVD
ranged from 0.2% for stable angina to 7% for SAH.
Further, we show that age (strongly), and to a lesser
extent diabetes and hypertension, modify associations
between smoking and CVDs. All these findings have impli-
cations for ‘precision medicine’ in targeting primary
prevention strategies. Clinicians can now provide patients
with greater clarity about the heterogeneous hazards of
smoking across a broad range of CVD presentations, and
greater accuracy of risk prediction for specific types of
CVD. In an ageing population, patients need to be informed
how smoking affects lifetime risks of different CVDs, for ex-
ample lifetime risks of PAD and AAA are no lower than
risks of MI. Further, younger people confident that CVD
risk will disappear after quitting should know that this does
not apply across all CVDs; and, in those who manage to
quit risks of PAD, AAA and unheralded coronary death re-
main increased even after 10 years. Our findings also em-
phasise the importance of defining specific cardiovascular
endpoints, and of understanding the composition of aggre-
gate endpoints used in observational studies, clinical trials
and cost-impact evaluations of interventions to promote
smoking cessation. They also stress the need to report and
consider CVD-specific information when assessing hetero-
geneity in meta-analyses and in design and interpretation of
gene-environment interaction studies.39
Two public health interventions were implemented dur-
ing the study period. In 2004, general practitioners began
to be financially rewarded for recording information on
smoking status and this may have triggered risk-lowering
interventions among smokers. In 2007, the public smoking
ban was introduced in England and this might have low-
ered passive exposure among non-smokers. Whereas there
is good evidence that the smoking ban was associated with
reduced rates of MI in the UK and elsewhere,3 we did not
find strong evidence that either of these initiatives changed
the associations of smoking status across a wide range of
CVDs in the present study.
Smoking status is among the most important pieces of
information that a healthcare professional can record.40
Our study highlights the prospective validity of such a
measure in research, and points to the need for quality-of-
care initiatives to improve recording. About a quarter of
patients (27%) had no clinical record of smoking status
and also details were lacking on age at initiation, patterns
and duration of smoking, amount of cigarettes smoked
and second-hand smoke exposure. More detailed measures
of smoking are likely to show stronger relationships with
disease. For example, among women selected from a na-
tional breast cancer screening programme,5 the amount of
cigarettes smoked was associated with stronger relative
risks of cause-specific mortality than current smoking. Our
findings support previous calls, embodied in a National
Institute of Health and Care Excellence (NICE) quality
framework,41 for healthcare professionals to regularly
question patients as a tool to encourage discussion,
review options currently available to support smoking
cessation and monitor progress made; and to record
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detailed information about smoking behaviour for research
purposes.
As research and meaningful re-use of EHRs is encour-
aged worldwide, ours is among the first large-scale cohorts
to demonstrate the potential of using linked clinically re-
corded health information on health-related behaviour for
testing new aetiological hypotheses. The large population-
based sample and number of CVD endpoints analysed, the
longitudinal design allowing differentiation between inci-
dent initial CVD presentations and progression of disease,
and the availability of information about a wide range of
common cardiovascular phenotypes are some of the
strengths of our study. There is evidence of the complete-
ness and validity of diagnostic coding of the original data
sources,42–44 and the use of linked individual patient data
from four different sources for the identification of end-
points minimized the likelihood of outcome status
misclassification.42,45
Several limitations are to be considered when interpret-
ing our findings. First, data for smoking and risk factors
were missing for some patients, but findings based on
multiply imputed data and complete case analyses were
consistent. Second, information on detailed smoking habits
(e.g. patterns, duration and amount of cigarettes smoked)
was unavailable and residual confounding cannot be com-
pletely excluded. However, adjustment for the main
known or suspected cardiovascular risk factors, for medi-
cation use and for patient birth cohort (data not shown)
had little effect on almost all the estimates. Third, smoking
status was self-reported by patients during consultations
with their general practitioner and might have been misre-
ported by some. Smoking status might also have changed
over time, and this could have resulted in underestimation
of associations (e.g. for CA-SCD) and overestimation of
the length of time required to achieve the risk levels of
never smokers after smoking cessation. Fourth, to define
CVDs we used data from four different EHR sources, each
of which has its own error. However, smoking associations
were robust to exclusion of primary care cases or non-fatal
cases; and we42 and others46 have provided evidence of the
validity of using linkages for endpoint follow-up. Fifth, we
were unable to resolve disease subtypes including systolic
or diastolic heart failure, which might mask an even
greater degree of heterogeneity. Finally, we cannot exclude
that some associations might have resulted from multiple
testing, and caution is required to interpret reported confi-
dence intervals.
Conclusion
The highly heterogeneous associations of smoking across
different types of cardiovascular phenotypes have
important implications for research, clinical screening and
risk prediction. They suggest the need to move away from
aggregate to disease-specific risk models that are more in-
formative for clinicians and policymakers in developing
and implementing strategies for the prevention of CVD.
Supplementary Data
Supplementary data are available at IJE online.
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